Eyenuk recently received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system, which automatically detects diabetic retinopathy. The company said this FDA clearance makes its system the only AI system that is FDA-cleared for use with multiple retinal cameras produced by different manufacturers.
Ascertain — a healthcare AI company creation platform formed last year by Northwell Health and Aegis Ventures — has launched its first startup. New York-based Optain, which has gained an initial seed investment of $12 million, is an AI company meant to enable earlier disease detection and prevention through retinal imaging.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company's AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.
The funding round was led by Signals Venture Capital and included participation by Talis Capital, Mutschler Ventures, IBB Beteiligungsgesellschaft and Cavalry Ventures.
The Palo Alto startup has developed an AI-based system that can screen the retinal images of newborn babies to highlight potential eye conditions that require follow-up and treatment.
Tucson, Ariz.-based healthcare startup Salutaris Medical Devices has raised $50,000 in debt financing so far in its quest to reach $1 million, according to a regulatory filing made with the SEC. The funding will support the 5-year-old company’s minimally invasive brachytherapy treatment for wet age-related macular degeneration. CEO Mike Voevodsky said in an email: “The device […]
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Oraya Therapeutics, one of California’s many healthcare startups, has distinguished itself from the crowd. The medical device company recently presented results from a two-year study showing its IRay, a low-voltage, stereotactic, radiosurgical system, is able to reduce or halt effects of wet age-related macular degeneration in treated patients and “signifcantly” lower the frequency of anti-VEGF injections […]
Using the 150-year-old eye chart today is a little like riding a horse and buggy around town, as Richard Tirendi sees it. To bring vision screening up-to-date and remove some of the human variability and subjectivity in it, Tirendi and his eye surgeon friend reinvented the eye chart in the form of a computer game. […]
An iPhone adapter with a companion app designed to make it easy to share high resolution images of the retinal nerve and fundus has received 510(k) clearance from the U.S. Food and Drug Administration. Welch Allyn’s iExaminer Adapter connects an ophthalmoscope — used to detect conditions like retinal detachment or glaucoma — to an iPhone. […]
A biopharmaceutical company that spun out of Cincinnati-based Akebia Therapeutics just eight months ago has raised $27 million to support development and clinical trials of its drug for diabetic macular edema. Novartis BioVentures led Aerpio Therapeutics’ series A, which also saw participation from Venture Investors LLC, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Phase 3 trials are underway for a biotechnology company’s drug to treat non-infectious Uveitis, an inflammatory eye disease and the fourth leading cause of blindness among the working age population in the United States. The move is intended to satisfy safety and efficacy issues raised in a complete response letter by the U.S. Food and […]